PBAC's latest decision on Sucroferric oxyhydroxide: Noted (2015). Considered for Treatment of hyperphosphataemia in patients undergoing dialysis for chronic kidney disease.
PBAC outcome
Noted
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2014
Submissions
2
2014 → 2015
Eligible population
Patients with hyperphosphataemia undergoing dialysis for chronic kidney disease, with serum phosphate >1.6 mmol/L or calcium-phosphate product >4, where condition is not adequately controlled by calcium alone.
Therapy area
Endocrinology
Line of therapy
Not applicable
ICER note
Not applicable; this is a minor submission regarding restriction clarification, not a full economic evaluation.
Submission history
Nov 2014: Recommended with restriction · Authority Required